AQUILAB Ushers In MVision’s Innovative and Guideline-Compliant AI Segmentation Solution to France

Helsinki – 29th of September 2021 – MVision AI, the leading service provider of guideline compliant radiotherapy software, announces a new distribution partnership with AQUILAB, the chief provider of revolutionary oncology software solutions throughout France. 

The agreement entitled AQUILAB the rights to distribute products and services of MVision AI in France. AQUILAB and MVision AI will support the commitment to help oncology departments to receive the highest quality, guideline-based, deep learning radiotherapy solution throughout France. MVision AI’s team will be working closely with AQUILAB to ensure the distribution of swift, steady, and secure radiotherapy services. 

The agreement entitled AQUILAB with the rights to distribute products and services of MVision AI in France. MVision AI and AQUILAB are committed to helping oncology clinics to provide the most innovative, guideline-compliant, AI segmentation radiotherapy solutions for patients. 

“For more than 20 years, AQUILAB (www.aquilab.com) has developed advanced software solutions to improve quality in cancer treatment. In Radiotherapy, we offer contouring solutions, participate in RT QA in clinical trials and we are fully involved in many training workshops. In all these activities, we see that harmonization and standardization of the contouring process is one of the main issues to reduce variability and improve quality in radiotherapy treatments. In this context, we are very happy to have a partnership with MVision, to propose automatic AI contouring solutions in French language countries. We think that this solution, based on international guidelines, will permit our users to fully improve the performance and the quality of their contouring workflow,” said David Gibon, President and CEO of AQUILAB. 

As stated by Mahmudul Hasan, CEO, and co-founder of MVision AI, “MVision AI is delighted to partner with AQUILAB to bring guideline-compliant AI segmentation for French patients. France is pioneering deep learning development in its implementation and advocacy of AI initiatives. We are glad to see France’s enthusiasm and curiosity towards artificial intelligence. We are grateful for this support. We have been looking forward to introducing swift, reliable, and high-quality AI segmentation solutions for cancer patients undergoing radiotherapy.” 

Learn more about incorporating AQUILAB’s solutions into your clinic here:

250 rue Salvador Allende – 59120 Loos – France

 Tel:  +33 3 69 61 51 51

 Website: https://www.aquilab.com/ 

Email: info@aquilab.com

LinkedIn: https://www.linkedin.com/company/aquilab/ 

Discover guideline-compliant AI segmentation with MVision here:

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@ mvision.ai 

LinkedIn: https://fi.linkedin.com/company/mvisionai 

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

Previous Post
New Horizons for Patients with Endometrial Cancer
Next Post
MVision’s On-Premise Solutions
Sign up for newsletter

    Menu